Hikma Pharmaceuticals’ fair value estimate has been nudged down from £22.66 to £22.00 per share, a small adjustment that ...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) today announced unaudited preliminary financial results for the fourth quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback